Non-Profit Trusted Source of Non-Commercial Health Information
The Original Voice of the American Academy of Anti-Aging, Preventative, and Regenerative Medicine
logo logo
Genetic Research Inflammation Metabolic Dysfunction Prevention

Metabolic physiology: New approach against fatty liver

1 month ago

1176  0
Posted on Jun 19, 2024, 6 a.m.

Fatty liver disease (steatotic liver disease, SLD for short) is increasingly causing failure of the liver as a vital organ.

A team led by researchers from the Institute of Metabolic Physiology at Heinrich Heine University Düsseldorf (HHU) in collaboration with the German Diabetes Centre (DDZ) and other partners has now discovered that a saturated fatty acid in blood vessels leads to the production of the signalling molecule SEMA3A, which closes the 'windows' in the blood vessels. This hinders the transport of fat from the liver to the adipose tissue.

In the journal Nature Cardiovascular Research, the researchers report that the windows open again and the fat in the liver is reduced when SEMA3A is inhibited.

In particular, 'metabolic dysfunction-associated SLD' (MASLD for short) can develop due to adverse lifestyle factors such as a high-energy diet and little exercise. It already affects around a third of all people worldwide. Initially, MASLD has no pathological effects, but it can develop into inflammation of the liver.

In the long term, this may lead to liver cirrhosis, liver failure or even liver cancer. There is no substitute procedure that can take over the function of the liver in the long term, such as dialysis for kidney failure. Those affected are at high risk and may only be cured by a liver transplant.

In addition, people with MASLD have an increased risk of developing type 2 diabetes mellitus or dying from cardiovascular diseases. Obesity favours MASLD, but not all obese people are affected. And conversely, slim people can also develop the disease.

The molecular causes of the development of MASLD are not fully understood. A team of researchers from HHU, the DDZ (Leibniz Centre for Diabetes Research at HHU), Düsseldorf University Hospital (UKD) and Forschungszentrum Jülich (FZJ) have now discovered an important aspect that explains how MASLD develops.

The leading role is played by windows (Latin: fenestrae) in the endothelial cells of blood vessel, through which substances are exchanged between liver cells and blood. The liver uses these tiny windows to release excess fat particles into the adipose tissue via the bloodstream. The researchers discovered that these windows are closed by a mechanism in which the signalling molecule SEMA3A (semaphorin-3A) plays the central part. This molecule is produced in blood vessels when they are overly exposed to the saturated fatty acid "palmitic acid."

Sydney Balkenhol from the Institute of Metabolic Physiology at HHU and the DDZ, first author of the study now published in Nature Cardiovascular Research, points to a discovery made by the team using scanning electron microscopy: The "windows" in the smallest blood vessels of the liver were also closed in mice with fatty liver and type 2 diabetes mellitus.

Dr Daniel Eberhard, the other first author, adds: "We were also able to reverse the effect. By inhibiting the signalling molecule, we could defat the liver and thus improve its function again."

Corresponding author Dr. Eckhard Lammert, Professor and Head of the Institute of Metabolic Physiology at HHU and the Institute of Vascular and Islet Cell Biology at the DDZ, hopes that the discoveries will also lead to a therapeutic approach for humans in the long term: "It may be possible to use the SEMA3A signalling molecule we identified to prevent MASLD and its consequences at an early stage. However, we first need to investigate the processes in humans in detail."

As with anything you read on the internet, this article should not be construed as medical advice; please talk to your doctor or primary care provider before changing your wellness routine. This article is not intended to provide a medical diagnosis, recommendation, treatment, or endorsement. Additionally, it is not intended to malign any religion, ethic group, club, organization, company, individual, or anyone or anything. These statements have not been evaluated by the Food and Drug Administration. 

Content may be edited for style and length.

References/Sources/Materials provided by:

arne.claussen@hhu.de

This article was written by Dr. Arne Claussen at Heinrich-Heine University Duesseldorf

https://www.hhu.de/en/news-article/neuer-ansatz-gegen-fettleber-1

https://www.hhu.de/en

http://dx.doi.org/10.1038/s44161-024-00487-z

WorldHealth Videos